In a significant development for cancer treatment, Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focusing on the development of targeted therapies for oncology, announced its plan to initiate a New Drug Application (NDA) submission for its investigational drug, gedatolisib. This submission is for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) and will occur under the U.S. Food and Drug Administration’s (FDA) Real-Time Oncology Review (RTOR) program. The initiative allows for a streamlined process that enables the agency to evaluate key efficacy and safety data earlier than traditional applications.
The announcement, made on August 27, 2025, illustrates Celcuity’s strategic approach to expedite the approval process for gedatolisib, a product derived from robust clinical insights. The FDA’s acceptance of the NDA submission is a critical step, as it indicates the regulatory body’s confidence in the data being reviewed. With a rolling submission expected to begin in September 2025, Celcuity plans to leverage topline efficacy data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial. The target for completion of the NDA submission is set for the fourth quarter of 2025.
This momentous development comes amid challenging financial circumstances for Celcuity. The company reported a revenue stagnation on a year-over-year basis for the second quarter of 2025, with no growth 0% contrasted sharply against the robust 40.07% revenue increase reported by many of its competitors in the same timeframe. Such figures reveal an intricate landscape where Celcuity must navigate both positive advancements in drug approval and the urgent need to bolster its financial position.
In addition to revenue stagnation, the company also recorded a net loss, a situation similarly experienced by many of its industry peers. The competitive landscape in the oncology sector remains steep, with companies pushing for advancement in their therapeutic offerings while managing fiscal responsibilities. This dual challenge highlights the urgency with which Celcuity must approach its next phases of development and commercialization.
As Celcuity continues to carve out its niche in targeted therapies for breast cancer, the success of gedatolisib could provide not only a pivotal clinical breakthrough but also a potential lifeline to improve its financial metrics and market position.
The upcoming critical phases in the NDA submission and the ongoing evaluation of its clinical data will be pivotal for Celcuity going forward. Investors and stakeholders will be closely monitoring these developments as the company seeks to make strides amidst the broader competitive dynamics at play.
Comments